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Abstract 
Interstitial cystitis (IC) is a chronic, non-bacterial cystitis that is marked by urinary 
frequency and urgency and/or severe pelvic pain. The causes of this disease are not clear, 
and effective treatments and efficient diagnostic disease markers have not been 
established. The objectives of this study were to identify proteins associated with IC.  
In Chapter I, urine proteins from IC patients and healthy subjects were analyzed 
through a comparative proteomics approach using two-dimensional differential in-gel 
electrophoresis (2D-DIGE) and NanoLC/MS/MS. The urinary neutrophil elastase 
concentration was significantly higher in IC patients with pain than in healthy subjects. 
Remarkably, elastase concentration was significantly increased in patients with small 
bladder capacity (median: 6.31 ng/mL in IC with a bladder capacity below 200 mL vs. 
1.15 ng/mL in IC with a bladder capacity equal to or above 200 mL and 0.18 ng/mL in 
healthy bladders, p < 0.01, respectively). Neutrophil elastase concentration was elevated 
in the urine of the IC patient subset with bladder pain and small bladder capacity. 
In Chapter II, biologically active proteins were purified and identified from IC patient 
urine samples, a complex biological source, using the biological readout of a serum 
response element-dependent luciferase reporter gene assay. With anion-exchange Mono-
Q and C4 reversed-phase columns, apparent sharp active peaks were obtained. However, 
more than 20 kinds of proteins were identified by mass spectroscopy (MS) from the active 
fractions, indicating that the purification was not complete. Since further purification was 
difficult, candidate molecules were chosen by studying the correlation between MS 
protein identification scores and bioassay responses of chromatographic fractions near 
the active peaks. As a result, EGF was nominated as a candidate molecule among the 
identified proteins because the elution profile of EGF was consistent with the bioassay 
5 
 
results, and the correlation coefficient of EGF between MS protein identification scores 
and bioassay responses was the highest among all identified proteins. With recombinant 
EGF, anti-EGF and anti-EGF receptor antibodies, EGF was confirmed to be the active 
substance found in IC patient urine. This approach required only 20 mL of urine and two 
column chromatographic steps. Combining bioassays of chromatographic fractions and 
MS protein identification may be useful for identifying biologically active substances 
from complex protein sources.  
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General Introduction 
Drug development is becoming increasingly difficult. Validated targets based on 
pathology have been exhausted and the stratification of responsive patients based on 
mechanism of drug action have been sought in accordance with medical economic 
pressures. In order to solve these problems, it is necessary to connect the understanding 
of pathological mechanisms and select targeted molecules according to the patient’s 
condition.  
To understand the pathological condition of a patient, it is necessary to analyze their 
clinical specimens. In a study using clinical specimens, several problems often emerge, 
such as the difficulty of collection, limited sample amount, and variation among 
individuals. Urine is a feasible noninvasive human sample to utilize. Therefore, the author 
focused on urine samples of patients with IC, a urological condition with no known cause 
or diagnostic markers. 
Bladder interstitial space is the area between the bladder epithelium and the muscle 
layer. Although inflammation in the bladder interstitial space is a feature of IC, the studies 
that indicate inflammatory histopathological changes and urinary changes are not 
confirmatory (Kuo 2014). The cause of IC and methods to diagnose it remain unclear or 
unknown. The common symptoms of IC such as urinary urgency, frequency, and pelvic 
pain, are major characteristics of this disease but infection and characterized pathology 
are absent. Proposed etiologies include dysfunction of bladder epithelial cells, 
neurological inflammation, mast cell hyperplasia, and afferent neuron hypersensitivity 
(Belknap et al. 2015). It is expected that biomarkers based on IC etiology could be used 
to select proper treatment. 
Decreased bladder capacity occurs along with urinary urgency and pelvic pain in IC 
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patients. This situation is thought to involve the transmitted sensation of urinary urgency 
before sufficient pooling of urine caused by an abnormality in the elastic fibers. This 
relationship between inflammation and the nerves is suggested based on the observation 
of mast cell hyperplasia in the muscle layer and adhesion of mast cells and the afferent 
nerve (Belknap et al. 2015). Thus immunogenic and neurogenic inflammation are 
suspected to be involved. Increased levels of factors such as IL-6, chemokines, and NGF 
can be observed by analyzing urine and serum (Kuo 2014). In addition, decreased bladder 
capacity is caused by organic changes such as decreased bladder smooth muscle elasticity 
and fibrosis. Further, glomerulation on the bladder wall is characteristically observed 
when expanded by hydrodistension. This phenomenon is assumed to result from the 
existence of fragile new blood vessels and angiogenesis, and is implicated in disease 
development. 
Identifying physiologically active molecules from biological samples is known to be 
challenging (Doonan and Cutler 2004). To approach this task, although molecular 
strategies are used such as cDNA cloning, conventional protein purification also remains 
a powerful method to identify molecules with objective biological activity. On the other 
hand, if the target component is only present in a trace amount, large amounts of starting 
materials must be used. This becomes a hurdle when attempting to purify proteins from 
clinical material. It has become possible to identify a protein from correlating biological 
behavior and identifying proteins during purification, even using clinical samples, 
because the technology to identify trace amounts of protein has progressed along with 
MS analysis technology (Domon and Aebersold 2006). 
G-protein coupled seven-transmembrane receptors (GPCRs) are known to be involved 
in various diseases and are targets of many therapeutic agents. GPCRs are activated by 
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physiological ligands and transduce various intracellular signals through coupled G-
proteins. Orphan GPCRs, whose ligands are not yet characterized, exist in the GPCR 
family and their functions are also unclear. GPR18, which the author focused on, is also 
an orphan GPCR (Martin et al. 2015). Although some reports suggested N-arachidonyl-
glycine as its physiological ligand (Console-Bram et al. 2014), some reports deny this 
activity (Finlay et al. 2016). Furthermore, it has also been suggested that GPR18 can 
transmit signals in the absence of a ligand (Qin et al. 2011, Finlay et al. 2016, Martin et 
al. 2015). 
In this study, the discovery of an IC diagnostic marker from the analysis of urine was 
attempted. In addition, the GPR18 ligand discovery was also attempted, using patient 
urine as a starting material.  
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Chapter I: Increased concentration of neutrophil 
elastase in urine from patients with interstitial cystitis 
 
1. Introduction 
IC is a chronic, non-bacterial cystitis that is marked by urinary frequency and urgency 
and/or severe pelvic pain (Elbadawi 1997). The quality of life of IC patients is sustained 
at an extremely low level because of their severe symptoms. The cause(s) of this disease 
are not clear, and effective treatments have not been established (Sant 1991). IC is 
currently defined by the criteria from the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) (Gillenwater and Wein 1988). IC has also been recognized as 
a heterogeneous syndrome. The International Continence Society selected the term 
“painful bladder syndrome” for IC (Abrams et al. 2002). Recently, Yamada et al. reported 
that apoptosis of microvascular endothelial cells in the bladder tissue of IC patients is 
related to the perceived pain, indicating a difference in pathogenesis between IC patients 
with and without pain (Yamada et al. 2007).  
Diagnosing IC based on biofluid profiling is a very attractive strategy. In a review of 
IC markers, a great need for easily measurable markers is expected (Wilkinson and 
Erickson 2006). Proteomics strategies can be used for identifying markers of disease-
specific states or molecular changes (Van et al. 2003, Liu and Ehrlich 2006). 2D-DIGE is 
a technique that compares two different samples on a single 2D gel. Although Liu et al. 
reported that several differentially expressed proteins in the urine of IC patients can be 
identified by combination 2D-DIGE following RP-HPLC, a concrete difference between 
IC patient profiles and healthy controls has not yet been reported (Liu and Ehrlich 2006). 
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Numerous reports suggest that neutrophils are a major player in acute inflammation 
(Moraes et al. 2003). Neutrophil elastase exists in neutrophil azurophilic granules and is 
a destructive enzyme based on its strong enzyme activity and low substrate specificity. In 
fact, a neutrophil elastase inhibitor is used in clinical settings to treat acute respiratory 
distress syndrome (Zeiher et al. 2002). In a clinical urine test, increased leukocyte count 
suggests the presence of inflammation in the lower urinary tract. However, there is little 
evidence regarding the participation of neutrophils in IC pathogenesis from tissue and 
urine analysis of IC patients (Messing and Stamy 1978, Elgebaly et al. 1992). Therefore, 
neutrophils are not thought to play a major role in IC pathogenesis.  
In the present study, the author investigated the proteins in urine associated with IC 
using 2D-DIGE and analyzed the concentration of neutrophil elastase in urine from 
patients with IC, comparing patients with and without bladder pain. 
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2. Materials and Methods 
2.1. Patients 
For 86 IC patients who satisfied the NIDDK criteria (Gillenwater and Wein 1988), the 
O’Leary-Sant questionnaire (O’Leary et al. 1997), determination of bladder capacity and 
a general urine test were performed. Leukocyte analysis in urine was performed by 
microscopic examination, and ≤4 leukocytes/view field (magnification 400X) in 10-fold 
concentrated urine was referred to as the leukocyte-negative group. The mean age of the 
patients with IC was 58.5 years (range 22-84 years), and 81% of these patients were 
female. Nine patients with Hunner’s ulcer were observed by cystoscopy. The patients 
were clinically classified into two groups according to whether the patients had lower 
abdominal pain and/or perineal pain on urination according to a previous report (Yamada 
et al. 2007). One group consisted of patients with bladder pain as the predominant 
symptom (n=73), and the other consisted of patients with urinary urgency, but no bladder 
pain, as the predominant symptom (n=13). Each group of IC patients was subdivided by 
bladder capacity, less than 200 mL and greater than or equal to 200 mL, which was 
defined using maximum urination volume in micturition diaries. The proportion of 
females of the four subgroups was 67-88%, and no remarkable bias in the proportion was 
observed. All nine patients with Hunner’s ulcer were classified into the with pain and 
small bladder group. The mean age of the 89 healthy volunteers (referred to as normal 
control), who did not complain of lower urinary symptoms, was 45.4 years (range 20-70 
years), and 73% were female. The urine from these healthy volunteers was not tested 
using the general urine test including leukocyte analysis. All volunteers were enrolled in 
accordance with the research plan approved by the ethics committee of both National 
Hospital Organization Sagamihara National Hospital and Astellas Pharma Inc. and gave 
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written informed consent 
 
2.2. Urine processing 
Spot urine samples were collected before hydrodistension in the case of IC patients. 
All urine samples were centrifuged at 3,000 rpm for 10 minutes and stored at -20 ºC. 
Before assaying, the specimens were thawed and centrifuged.  
 
2.3. 2D-DIGE analyses 
To determine whether characteristic proteins in the urine of IC patients could be 
detected in a comparison between IC patients and healthy individuals, 2D gel 
electrophoresis was performed using the 2D-DIGE system (GE Healthcare Bio-Sciences 
Corp., Piscataway, NJ). In brief, after healthy and IC urine samples were labeled with 1-
(5-carboxypentyl)-1'-propylindocarbocyanine halide (Cy3) N-hydroxysuccinimidyl ester 
and 1-(5-carboxypentyl)-1'-methylindodi-carbocyanine halide (Cy5) N-
hydroxysuccinimidyl ester fluorescent dyes, respectively, the two labeled urine samples 
were mixed and separated with 2D gel electrophoresis, and then scanned using two 
distinct excitation and emission wavelengths specific for Cy3 and Cy5, respectively   
 
2.4. MS analysis 
Protein spots of interest were excised from the gel, and then subjected to in-gel trypsin 
digestion (Shevchenko et al. 1996). The digested peptide mix was injected onto a Pepmap 
C18 capillary 0.075 x 150 mm LC column (LC-Packings, Amsterdam, The Netherlands). 
The peptides were separated at a flow rate of 200 nL/min with a linear gradient of 
acetonitrile in 0.1% formic acid. The LC effluent was directly interfaced with the 
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nanoelectrospray ion source on a Q-TOF Ultima API mass spectrometer (Waters, Milford, 
MA) or on an LCQ iontrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). 
Protein identification was performed using MASCOT software (Matrix Science, London, 
UK).   
 
2.5. Protease substrate 
Peptide substrates were purchased from Peptide Institute, Inc., Japan. All substrates 
were designed to quantify protease activity by measurement of MCA fluorescence: 3090-
v, Gly-Pro-MCA; 3091-v, Leu-MCA; 3108-v, Suc-Gly-Pro-Leu-Gly-Pro-MCA; 3110-v, 
Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA; 3120-v, Suc-Leu-Leu-Val-Tyr-MCA; 
3124-v, Lys-Ala-MCA; 3132-v, Lys-MCA; 3133-v, Suc-Ala-Ala-Ala-MCA; 3147-v, Ala-
MCA; 3148-v, Phe-MCA; 3149-v, Met-MCA; 3150-v, Suc-Ile-Ile-Trp-MCA; 3153-v, 
Suc(OMe)-Ala-Ala-Pro-Val-MCA; 3156-v, Z-Val-Lys-Met-MCA; 3160-v, Suc-Ala-Glu-
MCA; 3176-v, Z-Leu-Arg-Gly-Gly-MCA; 3177-v, Z-Leu-Leu-Leu-MCA; 3195-v, Ac-
Ile-Glu-Thr-Asp-MCA; 3201-v, Ala-Ala-Phe-MCA; 3209-v, Z-Ala-Ala-Asn-MCA 
(Table 1-1).  
 
2.6. Purification of protease in urine 
After centrifugation and filtration, 100 mL of IC urine was applied on a concanavalin 
A sepharose column (GE Healthcare), which was washed with 20 mM Tris-HCl, 0.5 M 
NaCl, and then eluted with 20 mM Tris–HCl, 0.5 M NaCl, 0.5M α-D-methylmannoside 
(pH 7.4). After concentration with an ultrafiltration membrane of MWCO 10,000, the 
eluent was applied on an anion-exchange chromatography column (Mono-Q HR 5/5, GE 
Healthcare), which was washed with 50 mM Tris-HCl, 0.1% CHAPS (pH 8.0), and then 
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eluted using a linear gradient from 0 to 1 M NaCl in 50 mM Tris–HCl, 0.1% CHAPS (pH 
8.0). After the fractions eluted with 0.3-0.5 M NaCl were collected and concentrated, they 
were applied on a size-exclusion chromatography column (Superdex 200 HR 10/30, GE 
Healthcare), and then fractionated using 50 mM Tris-HCl, 0.1% CHAPS (pH 8.0), 1 M 
NaCl at a flow rate of 0.5 mL/min. The fractions eluted at 38-48 min were collected and 
concentrated, and then electrophoresed on 4-20% polyacrylamide gels and stained with 
MS-compatible silver staining (Daiichi-kagaku, Japan).  
 
2.7. Measurement of neutrophil elastase activity 
To confirm whether neutrophil elastase was specifically upregulated in IC urine against 
the urine of the normal control, the activity of neutrophil elastase in urine was quantified. 
Eighty-six IC patients and 89 healthy control subjects were analyzed for peptide substrate 
digestive activity. Each group of IC patients with pain and urgency was subdivided by 
bladder capacity. Urine samples were reacted with neutrophil elastase substrate of 0.1 
mM Suc(OMe)-Ala-Ala-Pro-Val-MCA in 0.2 M triethanolamine, 1 M NaCl, 0.02% NaN3 
and 0.1% PEG6000 at 37ºC overnight. The activity of purified human neutrophil elastase 
(Sigma-Aldrich, St Louis, MO) was also measured to estimate the amount in urine as 
activity. Increased fluorescence was measured at an excitation wavelength of 380 nm and 
an emission wavelength of 460 nm using a Safire fluorescent microplate reader (Tecan, 
Switzerland).  
 
2.8. Analysis of data 
Data are expressed as the mean value and the standard error of the mean for each group. 
Comparisons between groups was made using the Kruskal-Wallis H test. When the test 
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showed significant differences, pairwise comparisons were tested by the Wilcoxon rank-
sum test. A value of p < 0.05 was considered to have statistical significance. 
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3. Results 
3.1. Identifying neutrophil elastase from the urine of IC patients  
The pattern of protein spots in IC urine was clearly different from the pattern of healthy 
urine as determined by 2D-DIGE. Several spots around 40 kDa were elevated in the 
profile of IC urine (Fig. 1-1). These spots were identified as human serum albumin by 
MS analysis after in-gel digestion. However, the observed molecular weight was lower 
than the known molecular weight of albumin (~70 kDa). Therefore, it was concluded that 
albumin was degraded in IC urine, possibly through protease activity. 
First, we searched for sensitive small peptide substrates to detect protease activity in 
IC patient urine. Protease activities in urine from IC patients and control volunteers were 
measured using 20 peptide substrates (Table 1-1). Only one peptide substrate, 3153-v 
(Suc(OMe)-Ala-Ala-Pro-Val-MCA), was differentially digested by IC urine (Fig. 1-2). 
The author next purified the protease using this substrate to determine the activity during 
the purification process. After lectin affinity, anion-exchange, and gel-filtration 
chromatography (Fig. 1-3A), proteins containing purified fractions were visualized by 
SDS-PAGE and silver staining. A broad protein band was observed around 35 kDa (Fig. 
1-3B). Two peptide fragments were identified as neutrophil elastase by MS spectrometry 
and MASCOT software (Fig. 1-3C). The author confirmed that neutrophil elastase digests 
human serum albumin (data not shown), which was consistent with the existence of 
albumin degradation products in IC urine.   
 
3.2. Elastase activities in urine from IC patients 
As indicated in Fig. 1-4, elastase activity was clearly higher in the urine of IC patients 
with pain and a functional bladder capacity below 200 mL, compared to the other IC 
patient subgroups and healthy controls. These results suggest the presence of IC patient 
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subtypes, which can be classified by the activity of neutrophil elastase in the urine. There 
was no significant difference in neutrophil elastase activity between IC patients with 
urinary urgency, regardless of bladder capacity, and the normal controls (Fig. 1-4). The 
author next assessed the correlation between leukocyte count and neutrophil elastase 
activity in 73 IC patients with pain. Leukocyte-negative urine (< 4 leukocytes/view field) 
was observed in 53 patients (73%) (Fig. 1-5). Despite being leukocyte negative, 29 of 
these patients (55%) exhibited an increased neutrophil elastase concentration (more than 
1 ng/mL) (Fig. 1-5).   
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4. Discussion 
Elastase degrades elastin, consisting of elastic fibers, in smooth muscle (Betsuyaku 
2003). In the lung, elastic fiber degradation results in decreased compliance and increased 
tissue stiffness (Nishina et al. 1997). Because several reports have indicated that 
endothelial cell apoptosis (Yang et al. 1996) and inflammatory mediator induction from 
epithelial cells via PAR2 receptor activation (Uehara et al. 2003) occur due to neutrophil 
elastase, neutrophil elastase may alter bladder function. Further studies are required to 
clarify whether neutrophils participate in IC pathophysiology. Furthermore, because of 
the low specificity of elastase, many urine proteins would be degraded, including serum 
albumin. Care in quantifying marker proteins in urine from IC patients is necessary. 
Based on the results, the elastase in IC patient urine was active. These results suggest 
that neutrophil elastase in IC urine exists in an active form that can exhibit protease 
activity, differing from the condition in serum where neutrophil elastase is not usually 
active because it is inactivated by alpha1-protease inhibitor (Weiss 1989). 
Neutrophil elastase in seminal plasma from chronic prostatitis patients is correlated 
with the neutrophil count (Ludwig et al. 2003). However, this study found that a 
significant amount of elastase activity was present even in leukocyte-negative urine. 
These results indicate that neutrophil elastase could exist in the urine of IC patients 
without the infiltration of neutrophils. Elastase origin and site of production are still 
unclear.  
The elastase concentration in the urine of IC patients with pain was higher than the 
elastase concentration in urine of IC patients with urinary urgency. There was no 
significant difference in elastase concentration between healthy controls and IC patients 
with urinary urgency only. A previous study found that kallikrein activity is significantly 
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associated with the degree of bladder pain (Zuraw et al. 1994). Although a precise 
discussion is difficult because normal controls and IC patients without pain were not 
compared in this study, urinary kallikrein activation was also low in IC patients without 
pain, similar to the results of our study. Yamada et al. observed that microvascular 
endothelial cell apoptosis in the bladder tissue of IC patients is related to the pain felt, and 
urinary components may stimulate sensory nerves and cause pain because the barrier 
function of epithelial cells is impaired by the apoptosis of microvascular endothelial cells 
in the subepithelial area (Yamada et al. 2007). 
Furthermore, neutrophil elastase level was then compared to the functional bladder 
volume reported in each patient’s urinary diary. The small-capacity group (less than 200 
mL) had higher neutrophil elastase levels than the large-capacity group (200 mL or above) 
in IC patients with pain. Nevertheless, in the group of IC patients with urinary urgency, 
because there was no difference in elastase level between patients with small and large 
bladder capacity, the disease condition was thought to vary according to whether the 
patient presented with pain or not. Although it has been reported that IC patients without 
pain have Hunner’s ulcer (Yamada et al. 2007), Hunner’s-type patients were classified 
into the subgroup with pain and small bladder volume in this study. We did not find any 
significant difference in elastase concentration between IC patients with and without 
Hunner’s ulcer (data not shown). 
A study that examined 13 urine markers for IC indicated that antiproliferative factor 
(APF) activity was differentially expressed and had the least overlap between IC and 
control populations (Erickson et al. 2002). This study suggests that APF level might 
become an IC diagnostic parameter. Recently, APF was found to have a sialoglycopeptide 
structure (Keay et al. 2004), however, no APF quantification method has been reported. 
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Because APF level must be determined by the incorporation of 3H-thymidine in cultured 
healthy bladder urothelial cells (Keay et al. 2004), this marker is unlikely to be adopted 
as a diagnostic tool in clinical settings.  
In conclusion, the author identified neutrophil elastase in the urine of IC patients using 
a proteomics-based approach. A significantly increased elastase concentration was 
observed in the urine of IC patients with pain compared to the level in IC patients with 
urinary urgency but without bladder pain as the predominant symptom. These results 
indicate that there may be a different disease etiology between the two groups. Moreover, 
these results also suggest that the existence of neutrophil elastase in urine is related to the 
pain felt by IC patients and may aid in the diagnosis of IC or painful bladder syndrome. 
Finally, to address the evaluation of elastase as a drug target, it will be necessary to 
analyze the correlation between neutrophil elastase and bladder function. 
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5. Tables 
 
Table 1-1.  Protease substrate   
 
 
 
  
3090-v Gly-Pro-MCA 
3091-v Leu-MCA 
3108-v Suc-Gly-Pro-Leu-Gly-Pro-MCA 
3110-v Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA 
3120-v Suc-Leu-Leu-Val-Tyr-MCA
3124-v Lys-Ala-MCA 
3132-v Lys-MCA 
3133-v Suc-Ala-Ala-Ala-MCA 
3147-v Ala-MCA 
3148-v Phe-MCA 
3149-v Met-MCA 
3150-v Suc-Ile-Ile-Trp-MCA 
3153-v Suc(OMe)-Ala-Ala-Pro-Val-MCA 
3156-v Z-Val-Lys-Met-MCA 
3160-v Suc- Ala- Glu- MCA 
3176-v Z-Leu-Arg-Gly-Gly-MCA 
3177-v Z-Leu-Leu-Leu-MCA 
3195-v Ac-Ile-Glu-Thr-Asp-MCA 
3201-v Ala-Ala-Phe-MCA 
3209-v Z-Ala-Ala-Asn-MCA 
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6. Figures  
 
 
Figure 1-1. Comparative analysis by two-dimensional gel electrophoresis of urine 
protein from IC patients and normal healthy subjects.   
The circles indicate spots that were predominantly observed in samples from IC patients. 
In addition, the arrows indicate the breakdown fragments from human serum albumin. 
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Figure 1-2. Substrate specificity of protease in urine from IC patients.   
The activities are shown as a difference in fluorescence intensity between the value of IC 
urine and that of control volunteers. The peptide, 3153-v (Suc(OMe)-Ala-Ala-Pro-Val-
MCA), is an elastase substrate. The sequences of other peptide substrates in this figure 
are described in the Material and Methods. 
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Figure 1-3. Identification of neutrophil elastase from urine from an IC patient.  
(A) Chromatography of IC urine using a size-exclusion chromatography column. The 
dotted line and solid line show absorbance at 280 nm and elastase activity, respectively. 
The fraction indicated by the arrow was analyzed by SDS-PAGE. (B) SDS-PAGE of the 
fraction. (C) The peptide sequence identified by NanoLC/MS/MS (Q-Tof) is indicated in 
red characters. 
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Fig. 1-4.  Elastase activities in urine from IC patients with pain, IC patients with 
urinary urgency, and the healthy control. 
Each group of IC patients was subdivided into two groups (less than 200 mL and more 
than or equal to 200 mL) based on maximum bladder volume reported in the patient 
urinary diary. Elastase activity was measured as the digestion of peptide substrate. Each 
bar indicates the mean value, and the vertical line indicates the standard error of the mean 
for each group. The Wilcoxon rank-sum test was used to compare patients and the control. 
All statistical tests were two sided.   
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Fig. 1-5.  Elastase activities and leukocyte counts (leukocytes/view field) in the 
urine of IC patients with pain. 
The bar in the graph means the median.  
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Chapter II: Combining MS protein identification and 
bioassay of chromatographic fractions to identify 
biologically active substances from IC patient urine 
 
1. Introduction 
The purification and identification of biologically active proteins present in minute 
amounts from biological sources such as urine is still a difficult task (Doonan and Cutler 
2004). This process requires a large sample volume and many separation steps for 
purification (Mount et al. 1985, Jaspar and Franchimont 1987). Nevertheless, recent 
progress in MS has dramatically changed protein analysis (Domon and Aebersold 2006). 
With MS, smaller protein samples can be used than sample sizes used in classical protein 
identification methods such as N-terminal peptide sequencing. 
IC is a chronic, non-bacterial cystitis that is characterized by urinary frequency and 
urgency and/or severe pelvic pain (Elbadawi 1997). The International Continence Society 
also selected the term “painful bladder syndrome” for IC (Abrams et al. 2002). The 
quality of life of IC patients is extremely low because of their severe symptoms. The 
pathogenesis of IC is unclear, and effective treatments have not been established. To 
elucidate mechanisms of IC pathogenesis, the author performed gene expression analysis 
in IC bladder tissues using GeneChip technology and found that mRNA expression of, a 
G-protein coupled receptor 18 (GPR18), was higher in IC bladder tissues compared to the 
level observed in normal control tissue (data not shown). 
In the present study, the existence of an active substance in IC urine was suggested 
from a serum response element (SRE)-dependent luciferase reporter bioassay in a 
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recombinant HEK293 cell line stably expressing GPR18. The SRE is known to be 
targeted by multiple signaling cascades (Cahill et al. 1996). The author attempted to 
purify the active substance from a small volume of IC urine using chromatographic 
techniques. Among the many proteins identified from partially purified samples, we 
clearly nominated epidermal growth factor (EGF) as a candidate molecule judging by the 
correlation between the bioassay of chromatographic fractions and MS protein 
identification. With recombinant EGF, anti-EGF and anti-EGF receptor antibodies, EGF 
was confirmed to be the active substance found in IC urine. 
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2. Materials and Methods 
2.1. Materials and reagents 
Sequencing grade modified trypsin was purchased from Promega Co. (Madison, WI), 
Vydac C4 (0.46 cm inner diameter × 15 cm) was purchased from the Separations Group 
(Hesperia, CA), Sep-Pak C18 and Rapigest SF was purchased from Waters (Milford, MA), 
Mono Q HR 5/5 (0.5 cm inner diameter × 5 cm) was purchased from GE Healthcare Bio-
Science Corp (Piscataway, NJ), recombinant human EGF was purchased from PeproTech 
Inc. (Rocky Hill, NJ), anti-human EGF antibody was purchased from R&D Systems, Inc. 
(Minneapolis, MN), anti-EGF receptor antibody was purchased from EMD Biosciences, 
Inc. (La Jolla, CA), PepMap C18 cartridge (0.3 mm inner diameter x 5 mm, 5 µm) was 
purchased from LC-Packings (Amsterdam, The Netherlands), nano-HPLC capillary 
column (0.075 mm inner diameter × 150 mm, C18, 5 µm) was purchased from Nikkyo 
Technos (Tokyo, Japan), pSRE (serum response element)-luciferase reporter plasmid was 
purchased from Stratagene (La Jolla, CA), Lipofectamine 2000 and Dulbecco's modified 
Eagle's medium were purchased from Invitrogen (Carlsbad, CA). Human spleen cDNA 
was purchased from Clontech (Palo Alto, CA). pEF-BOS-neo vector (Mizushima and 
Nagata 1990) was donated by Prof. S. Nagata (Osaka University Medical School, Osaka, 
Japan). All other reagents were of analytical grade. 
 
2.2. IC patient 
The 31 IC patients satisfied the NIDDK criteria (Gillenwater and Wein 1988). The 
mean age of the IC patients was 58 years (range 19-82 years), 84% were female. The 
mean age of the 11 healthy volunteers without complaints of lower urinary symptoms was 
42 years (range 20-60 years), 82% were female. The patients and healthy volunteers were 
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enrolled in accordance with the research plan approved by the ethics committee of both 
the National Hospital Organization Sagamihara National Hospital and Astellas Pharma 
Inc. and gave written informed consent. 
 
2.3. Purification of an active substance from IC urine 
Random midstream urine samples were collected in 15- or 50-mL polypropylene 
conical tubes and immediately centrifuged at 3,000 rpm for 10 minutes at 4 ºC. The 
supernatant was immediately stored in the same kind of tube without any additives at -20 
ºC. The maximum storage period and the maximum number of freeze-thaw cycles of the 
urine samples were 6 years and 10 cycles, respectively. Just before use, the urine was 
thawed and immediately centrifuged 3,000 rpm for 10 minutes at 4 ºC. For purification, 
20 mL of the supernatant was applied to a reversed-phase Sep-Pak C18 cartridge 
prewashed sequentially with 90/10 (v/v) acetonitrile/water and with water. The cartilage 
was washed with water, and then eluted with 50/50 (v/v) acetonitrile/water. This fraction 
was concentrated with a SpeedVac concentrator (Thermo Electron, Waltham, MA), and 
cold ethanol was added, and the mixture was stored at 4 ºC for more than 30 min. After 
centrifugation at 21,000 g for 5 min, the precipitate was dried with the SpeedVac 
concentrator, dissolved with 0.25 mL of 20mM Tris-HCl (pH 8.0), and then injected on 
an anion-exchange column (Mono-Q HR 5/5). The mobile phases consisted of Solvent A 
(20mM Tris-HCl, pH 8.0) and Solvent B (20mM Tris-HCl, pH 8.0, 1M NaCl). The 
column was initially equilibrated at 0% B at a flow rate of 0.5 mL/min. The separation 
was performed by a linear gradient of 0% B to 100% B over 30 min at a flow rate of 1 
mL/min at room temperature. Detection was by UV absorbance at 280 nm. The fractions 
were manually collected at 1 min intervals into polypropylene microtubes, which were 
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used for the bioassay and MS protein identification. 
The Mono-Q fractions were further separated with a reversed-phase column (Vydac 
C4). The mobile phases consisted of Solvent A (0.1% TFA) and Solvent B (0.1% TFA in 
90/10 (v/v) acetonitrile/water). The column was initially equilibrated at 0% B at a flow 
rate of 0.3 mL/min. The separation was performed by a linear gradient of 0% B to 50% 
B over 30 min at a flow rate of 1 mL/min at room temperature. Detection was by UV 
absorbance at 280 nm. The fractions were manually collected at 1 min intervals into 
polypropylene microtubes, which were used for the bioassay and MS protein 
identification. The HPLC experiments were performed using an HP1090M liquid 
chromatograph (Agilent Technologies, Palo Alto, CA). 
 
2.4. MS analysis  
The collected fraction was dried with the SpeedVac Concentrator and dissolved with 
50 µL of 50 mM NH4HCO3 and 0.1% Rapigest SF. The reduction and alkylation were 
performed with 5 mM DTT at 60 ºC for 30 min and with 15 mM iodoacetamide at ambient 
temperature for 20 min. After 1 µg of trypsin was added, the reaction mixture was 
incubated at 37 ºC for 1 h, and then HCl was added at a final concentration of 0.1 M and 
centrifuged at 13,000 rpm for 10 min to remove Rapigest SF. The supernatant digested 
peptide mixture was concentrated on an online trap column (Pepmap C18), and then 
separated with a reverse-phase microcapillary column (nano-HPLC capillary column) 
using a CapLC ststem (Waters). The mobile phases consisted of Solvent A (2% 
acetonitrile, 0.1% formic acid) and Solvent B (90% acetonitrile, 0.1% formic acid). The 
column was initially equilibrated at 10% B at a flow rate of 200 nL/min. The separation 
was performed by a linear gradient of 10% B to 50% B over 35 min, 90% B over 10 min, 
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and 10% B over 15 min at a flow rate of 200 nL/min at room temperature. The LC effluent 
was directly interfaced with the nanoelectrospray ion source on a Q-TOF Ultima API 
mass spectrometer (Waters). An MS survey scan was obtained for the m/z range of 400-
1500, and MS/MS spectra were acquired for the two most intense ions from the survey 
scan with precursor charge limitation (2 or greater). Dynamic exclusion of 2-min duration 
was used to acquire MS/MS spectra from low-intensity ions. All the MS/MS spectra were 
converted into text files (.pkl) using Protein Lynx software (Waters, purchased in Feb 
2003) combining sequential scans with the same precursor, smoothing the spectrum with 
Savitzky-Golay smoothing, and measuring the peak top with a centroid top of 80%. 
Protein identification was performed using MASCOT software (Version 2.1.0, Matrix 
Science Inc, Boston, MA). An in-house customized database (built in Sep 2006, 224,925 
sequences) based on the NCBI non-redundant protein sequence database with species 
limitation (only human, mouse, rat, and bovine proteins can pass) and with locus 
redundancy removal by NCBI EntrezGene was used. The Mascot search parameters were 
as follows. Peptide tolerance was 0.45 Da and MS/MS tolerance was 0.15 Da 
(monoisotopic mass). Fixed modification of carbamidomethylation (Cys) and variable 
modifications of oxidation (Met), acetylation (N-terminus) and pyro-glu (Glu and Gln) 
were selected, and up to four missed trypsin cleavages were allowed. A protein score of 
40 (p < 0.05) and a peptide score of 25 were the minimum identification criteria, and 
manual examination was conducted for all proteins identified with fewer than 80 points 
on the protein score or fewer than four unique peptides. The criteria used for manual 
validation included (a) peptide fragment ions being clearly above base-line noise, (b) 
intense y or b ions corresponding to the N-terminal cleavage of proline or glycine and 
absence of C-terminal cleavage of proline or glycine (except where proline follows), (c) 
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major five fragment ions being interpretable, and (d) not matching a common contaminant 
(such as silicone or polyethylene glycol) or trypsin-derived signals. In addition, each 
MS/MS spectrum of proteins identified with a small number (one or two) of peptides was 
compared with the same spectrum of the same proteins (if it exists) identified using a 
large set (three or more) of peptides for further manual confirmation. If peptides matched 
to multiple database entries, the one RefSeq  accession number belonging to the species 
Homo sapiens was assigned for the identification protein. 
 
2.5. Bioassay  
The full-length cDNA of GPR18 (GenBankTM accession number NM_005292) was 
amplified by PCR with forward primer 5’-
GGGTCTAGAATGATCACCCTGAACAATC-3’ and reverse primer 5’-
GGGTCTAGATCATAACATTTCACTGTTTATA-3’ from human spleen cDNA and 
ligated into pEF-BOS-neo vector treated with XbaI. The stable recombinant HEK293 cell 
line expressing GPR18 and vector control were established by selecting G418-resistant 
cells after transfection with the pEF-BOS-neo-GPR-18 vector and the pEF-BOS-neo 
vector, respectively. The cells were seeded onto collagen-coated 96-well plates (10,000 
cells/well) in Dulbecco’s modified Eagle’s medium supplemented with 10 % fetal bovine 
serum, 100 units/mL penicillin, and 100 µg/mL streptomycin and incubated at 37 ºC in a 
5% CO2 humidified atmosphere for 24 h and then transfected with pSRE-luciferase 
reporter plasmid (100 ng/well) using Lipofectamine 2000. After 24 h, 10 µL of urine 
samples were added into the wells and incubated for 16 h. After discarding the medium, 
the cells were lysed in 20 µL of solubilization buffer (0.5 mM MgCl2, 10 mM DTT, 0.1% 
Triton X-100, 10 mM Tris, pH 7.8) were added into the wells. Luciferase activity 
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measured by a Dynatech ML3000 luminometer (Dynatech Laboratories, Chantilly, VA) 
is expressed as relative light units.  
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3. Results 
3.1. Activity of IC and normal volunteer urines in an SRE-dependent luciferase 
reporter gene bioassay 
We found the existence of an active substance in IC urine in the SRE-dependent 
luciferase reporter gene bioassay using a recombinant HEK293 cell line stably expressing 
GPR18. The SRE is targeted by multiple signaling cascades (Cahill et al. 1996). The 
results are shown in Fig. 1. Urine from IC patients showed higher bioassay activity than 
healthy volunteer urine (Fig. 2-1A). The signal from the HEK293 cell line expressing 
GPR18 was higher the signal of these cells expressing the empty vector control (Fig. 2-
1B), suggesting that the elevated bioassay activity observed was related with GPR18. The 
activity was lost with protease digestion or heat treatment (data not shown), indicating 
that this substance is a polypeptide.  
 
3.2. HPLC chromatography and purification of IC urine 
The author tried to purify the active substance using column chromatography. The 
purification scheme is shown in Fig. 2-2. With Mono-Q anion-exchange column 
chromatography, two main active peaks were obtained (Fig. 2-3A). The author collected 
the two active fractions designated as AEX-12 and AEX-14, which were further separated 
with C4 reversed-phase chromatography. From the AEX-12 fraction, one active peak was 
obtained (Fig. 2-3B). The fraction was dried and digested with trypsin, and then identified 
with MS. Although the peak seemed very sharp, more than 10 proteins were detected in 
the active fraction of No. 34 from AEX-12 (Table 2-1). Whereas, from the AEX-14 
fraction, one relatively broad active peak eluted at three fractions was obtained (Fig. 2-
3C). More than 20 proteins were also identified in the three active fractions of No. 34-36 
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from AEX-14 (Table 2-1). 
 
3.3. Correlation between MS identification and bioassay results of active fractions 
The author attempted to purify the active fractions using additional size-exclusion, 
cation-exchange, or lectin affinity chromatography, but failed to achieve satisfactory 
purification. 
Since further purification was difficult, we utilized another strategy. The fractions 
eluted near the active peaks on the reversed phase chromatography were identified with 
MS, and then the elution profile of the proteins was compared with the bioassay responses. 
The results are shown in Table 1. EGF was the only protein identified in the active 
fractions of both No. 34 of AEX-12 and No. 34-36 of AEX-14 (Table 2-1).  
 
3.4. Comparison between product ion spectrum of EGF tryptic peptide and from 
the fraction 
The product ion spectrum of EGF in the sample was identical with the spectrum of 
authentic recombinant EGF (Fig. 2-4). The correlation coefficient of EGF between 
MASCOT scores and bioassay responses was the highest among those of the identified 
proteins (Table 2-1). Therefore, we nominated EGF as the most prominent active 
candidate molecule. 
 
3.5. IC urine activity was inhibited with anti-EGF and anti-EGF receptor 
antibodies 
To confirm whether the active substance in IC urine was EGF, we studied the effect of 
authentic recombinant EGF protein, anti-EGF and anti-EGF receptor antibodies for the 
bioassay. The recombinant EGF showed a dose-dependent response in the bioassay just 
as IC urine did (Fig. 2-5A, 2-5B). The concentration of EGF in the IC urine sample used 
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for this purification was estimated to be approximately 10 ng/mL because the signals of 
1 μL and 10 μL IC urine corresponded to signal intensities of 0.01 ng and 0.1 ng EGF, 
respectively. The bioassay activity of recombinant EGF and IC urine were completely 
inhibited upon the addition of anti-EGF and anti-EGF receptor antibodies (Fig. 2-5C to 
2-5F). These results indicate that the active substance in IC urine was EGF. 
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4. Discussion 
EGF is a 53-amino acid peptide with three internal disulfide bonds and a variety of 
biological activities (Mount et al. 1985, Jaspar and Franchimont 1987). EGF in urine is 
reported to have C-terminal heterogeneity, occurring in forms such as the des-arginyl 
form (Mount et al. 1985, Jaspar and Franchimont 1987), which is likely the cause of the 
multiple peaks observed with Mono-Q chromatography. It has also been reported that the 
mean EGF concentration of 20 ng/mL observed in IC urine is higher than the 
concentration of 2 ng/mL observed in the control (Zhang et al. 2003), which was 
consistent with our data that the EGF-related activity in IC urine was higher than EGF-
related activity in control urine. In previous studies, EGF was purified from a large 
volume of human urine with many chromatographic steps, such as from 330 L with four 
steps (Mount et al. 1985) and 500 L with six steps (Jaspar and Franchimont 1987). In this 
report, EGF was identified as the active substance from 20 mL of IC urine with only two 
chromatographic steps (Fig. 2-2). 
A decrease in the necessary sample amount for protein identification was achieved with 
MS, but at the same time, many kinds of proteins were identified from a partially purified 
sample, making it difficult to choose a candidate molecule for validation. This report 
shows that it is possible to select a suitable candidate molecule among many proteins 
identified with MS by judging from the correlation between MS protein identification and 
bioassays of chromatographic fractions. This approach does not require complete 
purification. MS protein identification for monitoring chromatographic fractions in 
combination with a bioassay may be useful for similar cases. 
Because the signal of the HEK293 cell line expressing GPR18 was higher than the 
signal of HEK293 cells expressing the empty vector control, we hypothesized that a 
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GPR18-related active substance existed in IC urine. However, the complete inhibition of 
the signal in IC urine upon the addition of an anti-EGF or anti-EGF receptor antibody 
clearly indicated that the signal was transduced through EGF and EGF receptors. The 
response of the GPR18-expressing HEK293 cell line was higher than the response of the 
controls might be due to enhanced EGF signaling in the HEK293 cell line upon GPR18 
overexpression. Some reports indicate that GPR18 constitutively activates anti-apoptosis, 
receptor trafficking, and intracellular cAMP elevation pathways (Qin et al. 2011, Finlay 
et al. 2016, Martin et al. 2015). 
In this study, the elution profile of proteins from MS identification was evaluated with 
semi-quantitative MASCOT identification scores. Other methods of quantitative MS 
analysis, such as iTRAQ, have also been reported (Zieske 2006). The use of quantitative 
MS protein analysis in conjunction with a bioassay and column chromatography should 
facilitate the process of nominating candidate proteins from small amounts of crude 
protein samples with minimum purification steps.   
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5. Tables 
 
Table 2-1. Correlation between protein identification and bioassay of active fractions 
separated with a C4 reversed-phase column from AEX-12 and AEX-14  
 
 
Proteins identified from only either AEX-12 or AEX-14 are not listed in this table. The 
number of unique peptides detected and sequence coverage (%) are the maximum 
values among those of the protein in the fractions listed. The sequence coverage (%) is 
calculated by dividing the number of amino acid residues of the identified peptide by 
that of the whole protein in the sequence database. Although the sequence coverage of 
EGF in this table is calculated as 1% by dividing 13 of the identified peptide 
(YACNCVVGYIGER) by 1030 of EGF in the database, the actual sequence coverage 
of EGF is calculated as 25% by dividing it by 53 of the mature EGF 17 existing in 
urine. To calculate the correlation coefficient, zero was used as the MASCOT score in 
the fraction where the protein was not identified. 
Peak ID
Fraction no. 32 33 34 35 36 32 33 34 35 36 37 38
Bioassay response 0.3 0.5 2.5 0.3 0.1 0.1 0.3 1.2 1.1 1.8 0.5 0.4 unique 
correlation peptides sequence
Accession no. Protein name coefficient detected coverage (%)
NP_001954 EGF 104 48 37 33 0.94 1 1
NP_002925 RNase A 107 26 56 0.73 2 19
NP_002037 GAPDH 48 60 31 0.68 1 2
NP_000601 CD44 189 122 123 63 174 124 0.66 3 4
NP_001091 alpha 1 actin 42 48 63 79 63 41 60 0.56 1 3
NP_002278 LAIR1 237 258 39 274 326 0.35 5 15
NP_000921 plasminogen activator 40 59 168 273 259 31 179 219 148 150 41 0.25 7 15
NP_057563 scotin 31 48 48 82 86 34 0.22 2 3
NP_001624 alpha-1-microglobulin 341 355 444 413 401 350 366 322 266 340 394 148 0.15 7 24
NP_056203 KLIP1 39 34 33 39 30 43 42 42 39 37 38 0.05 1 2
NP_000033 apolipoprotein H 114 86 0.05 3 11
NP_002945 ribosomal protein S27a 32 37 41 0.02 1 10
NP_116171 HAVCR2 134 84 0.00 3 11
NP_000945 PTGDS 37 204 197 29 89 173 163 -0.03 3 32
NP_000292 plasminogen 91 28 89 -0.06 2 2
NP_005414 trefoil factor 2 31 148 84 43 -0.08 3 22
NP_000302 prion protein 66 76 67 -0.09 1 4
NP_000884 kininogen 215 285 147 240 522 46 -0.12 10 29
NP_001008390 uromodulin 125 128 104 402 30 42 351 339 -0.15 8 13
NP_002995 SECTM1 93 39 46 -0.13 2 14
NP_000468 albumin 79 43 89 47 63 97 211 736 2246 -0.15 40 69
NP_000598 orosomucoid 1 27 308 78 -0.19 6 29
NP_000362 transthyretin 61 117 29 29 34 -0.25 2 19
NP_000055 complement component 3 80 40 -0.24 1 1
NP_443112 HGFL 80 107 75 31 202 244 32 -0.25 4 18
NP_004039 beta-2-microglobulin 55 32 -0.30 1 18
NP_002505 nov 78 60 55 -0.36 2 7
NP_001248 cadherin 13 184 167 63 -0.38 4 6
NP_006320 fibulin 5 26 78 60 -0.37 1 2
NP_976074 CD59 173 37 120 28 -0.38 4 25
NP_000129 fibrillin 1 70 113 36 -0.39 2 1
AEX-12 AEX-14
                                           MASCOT Score
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6. Figures 
 
 
Fig. 2-1.  The signal with HEK293 cell line with GPR18 
(A) Activity of IC and normal volunteer urines in the bioassay using the SRE dependent 
luciferase reporter gene with stable recombinant HEK293 cell line expressing GPR18. 
The activities in IC urines (n = 31) were higher than those of normal volunteer ones (n = 
11). The two sided P value was calculated by Wilcoxon rank-sum test. Each bar indicates 
the median of each group. (B) A dose dependent response in the bioassay with IC urine. 
pSRE-luciferase reporter plasmid was transfected into HEK293 cells containing pEF-
BOS-neo vector subcloned with GPR18 gene (GPR18) or pEF-BOS-neo vector (control). 
After transfection, the cells were stimulated with the indicated volume of IC urine. 
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Fig. 2-2.  Scheme of purification from IC urine. The methods are described in detail 
in Materials and Methods.   
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Fig. 2-3. HPLC chromatograms of purification from IC urine. 
(A) Mono-Q chromatogram of IC urine treated with C18 solid-phase extraction and 
ethanol precipitation. Two active fractions were obtained, designated as AEX-12 and 
AEX-14. (B) C4 chromatogram of AEX-12. Activity was observed in No. 34 fraction 
indicated by an arrow. (C) C4 chromatogram of AEX-14. Activity was observed in No. 
34, 35 and 36 fractions indicated by arrows. 
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Fig. 2-4. Product ion spectrum of EGF tryptic peptide  
Product ion spectrum of EGF tryptic peptide from the fraction 34 of AEX-12 (A) and 
from authentic recombinant EGF (B). 
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Fig. 2-5.  Effect of anti-EGF and anti-EGF receptor antibodies on SRE bioassay 
The activity of IC urine was inhibited with anti-EGF and anti-EGF receptor antibodies. 
After transfection of pSRE-luciferase plasmid into GPR18 expressing HEK293 cells, 
EGF (A) and IC urine (B) were added into wells and luciferase activity was measured. 
After anti-EGF antibody was added into wells, 0.2 ng EGF (C) and 10 μL IC urine (D) 
were assayed. After anti-EGFR antibody was added into wells, 0.2 ng EGF (E) and 10 μL 
IC urine (F) were assayed.  
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General Conclusion 
In the present study, a new understanding of IC etiology was obtained from analyzing 
biologically active substances in IC urine. Neutrophil elastase was observed for the first 
time in IC urine, which may aid in IC diagnosis and treatment. It is suggested that GPR18 
expression enhances EGF signaling, and EGF is known to exist in elevated concentrations 
in IC patient urine. Meanwhile, the identification of a trace amount of a physiologically 
active substance was efficiently achieved by the combination of a biological assay and 
MS analysis.  
In Chapter I, the presence of protease activity in IC urine was hypothesized through 
the observation of 2D-PAGE analysis (Fig. 1-1) and the protease in urine was identified 
as neutrophil elastase (Fig. 1-3). The concentration of neutrophil elastase in urine was 
higher in patients with low bladder capacity and pelvic pain than the concentration in 
patients without these conditions (Fig. 1-4). In Chapter II, it was observed that GPR18 
expression positively modulates EGF signaling (Fig. 2-5), suggesting that GPR18 
transmits this signal without its ligand.  
Neutrophil elastase is a protease with broad substrate specificity, and pathology onset 
has been suggested by degrading many substrates (Betsuyaku 2003, Nishima et al. 1997, 
Yang et al. 1996). In lung tissue, several studies revealed that neutrophil elastase induces 
emphysema and alveoli destruction, fibrosis, and pain via PAR2 activation (Uehara et al. 
2003). Furthermore, elastase decreases tissue elasticity by degrading elastic fibers 
(Betsuyaku 2003, Getie et al. 2005, Masood et al. 2015). Although patients with a high 
urine concentration of elastase represent only a portion of IC patients (Fig. 1-4), elastase 
may decrease bladder capacity and induce pelvic pain in those patients. That is, elastase 
inhibition could alleviate the IC symptoms. Since an orally active elastase inhibitor has 
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not been marketed so far for IC treatment, it will take some time until such a treatment 
may be utilized in the clinic.  
EGF is a bioactive factor that had been found as a gastric acid secretion-inhibiting 
substance that is present in the urine of pregnant women (Lugaro et al. 1965). In addition, 
EGF production is enhanced during wound healing and its activity is elevated in tissue 
repair, including repair of gastric ulcers (Konturek et al. 1991). Some IC patients have 
an ulcer called a Hunner’s ulcer on the bladder epithelium. Bladder mucosal epithelial 
disorder has been suggested based on the fact that glomerulation is observed when 
hydrodistension was performed (Gillenwater and Wein 1988). Because it is thought that 
a tissue repair reaction is occurring in IC patient bladders, the presence of EGF in IC 
patient urine indicates the phenotype of a tissue repair reaction. On the other hand, EGF 
signaling was enhanced by GPR18 expression (Fig. 2-1). This observation suggested the 
possibility that GPR18 can transduce signals in the absence of its ligand. Other previous 
studies also indicated that GPR18 can transmit signals without a ligand (Qin et al. 2011, 
Finlay et al. 2016, Martin et al. 2015). Qin et al. reported that GPR18 is involved in 
melanoma cell proliferation (Qin et al. 2011). Both EGF and GPR18 are relevant in 
epithelial cell hyperplasia, therefore an imbalance of destruction and repair in bladder 
epithelial tissue is considered to relate with IC pathology.  
Since elastase was identified in IC patient urine, the pathological relationship between 
elastase and IC has been discussed and development of diagnostics and therapeutics 
based on this discovery can be expected in the near future (You et al. 2012, Offiah et al. 
2013). The study that identified EGF was cited as due to its methodology for identifying 
bioactive substances from clinical samples using the combination of a bioassay and MS 
analysis (Sakurai et al. 2013). Lastly, the possibility of using urine markers to stratify IC 
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patients was identified in this study. This was an objective of this study. These results 
may be used to deliver the correct drug to patients. Although IC is thought to be one 
syndrome, the etiology in each IC patient is not the same. Therefore, it is expected that 
the results of this study will open the possibility of personalized therapy to alleviate 
symptoms of IC patients.  
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